Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Endocrine 1

Conditions

Neuroendocrine Tumors 11Adrenocortical Carcinoma 7Thyroid Carcinoma, Anaplastic 5Carcinoma, Neuroendocrine 4Thyroid Neoplasms 3Adrenal Cortex Neoplasms 3Ovarian Neoplasms 2Neoplasm Metastasis 2Carcinoma, Small Cell 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Vulvar Neoplasms 1Vascular Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pheochromocytoma 1Penile Neoplasms 1Pathologic Processes 1Parotid Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Paraganglioma 1Neoplasms, Unknown Primary 1Neoplasms, Germ Cell and Embryonal 1Multiple Myeloma 1

Interventions

relacorilant 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Processes × pembrolizumab × Endocrine × Clear all
NCT04373265 2024-02-23

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Corcept Therapeutics

Phase 1 Completed
15 enrolled
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Adrenal Gland Diseases, Adrenocortical Hyperfunction, Cushing Syndrome, Diabetes Mellitus, Type 2, Endocrine System Diseases, Hyperglycemia, Hypertension, Pathologic Processes, Glucose Intolerance, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡